SNAP-8

SNAP-8 (acetyl octapeptide-3, INCI name: Acetyl Octapeptide-3) is a synthetic cosmetic peptide developed by Lipotec as an extension of Argireline (acetyl hexapeptide-3). It is an 8-amino acid peptide with an N-terminal acetyl group and C-terminal amide, designed to competitively inhibit SNAP-25, a SNARE complex protein essential for neurotransmitter vesicle fusion at the neuromuscular junction. The proposed result is partial reduction of muscle contraction amplitude, attenuating dynamic wrinkle formation.

SNAP-8 is a cosmetic ingredient — not a pharmaceutical drug. It is not subject to clinical trial requirements or drug approval pathways. All efficacy data in circulation comes from manufacturer-sponsored studies (Lipotec), which are not independently peer-reviewed clinical trials. No independent RCT for SNAP-8 has been published in the medical literature.

The SNARE complex (SNAP-25 + syntaxin + VAMP) mediates synaptic vesicle docking and fusion at the neuromuscular junction, triggering acetylcholine release and muscle contraction. Botulinum toxin (Botox) irreversibly cleaves SNAP-25, producing complete neuromuscular blockade and flaccid paralysis of injected muscles — an effective but potentially dangerous approach.

SNAP-8 mimics the N-terminal region of SNAP-25 protein, competitively inhibiting its incorporation into the SNARE complex. This partial competitive inhibition: - Reduces (but does not eliminate) acetylcholine release at the neuromuscular junction - Attenuates muscle contraction amplitude without paralysis - Is reversible, producing a temporary effect that lasts while the peptide is present in tissue

The effect is quantitatively modest compared to botulinum toxin — estimated 30–65% wrinkle depth reduction vs. >90% for Botox in equivalent facial areas. Manufacturer data reports up to 63% reduction in periorbital wrinkle depth at 10% concentration over 28 days (digital profilometry), and approximately 30% improvement over Argireline at equivalent concentrations.

The two additional residues (Ala-Asp) in SNAP-8 vs. Argireline (6-mer) provide extended SNAP-25 N-terminal mimicry and are proposed to improve competitive inhibition kinetics, though this pharmacodynamic improvement has not been independently validated.